KalVista (KALV) Pharmaceuticals announced that it intends to offer, subject to market conditions and other factors, $110M aggregate principal amount of convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. KalVista expects to use the net proceeds from the contemplated offering for working capital and other general corporate purposes, including the commercialization of EKTERLY. KalVista may also use a portion of the net proceeds from the contemplated offering for investments in and acquisitions of other companies, products or technologies in the future. However, KalVista has no commitments or specific plans with respect to any such investments in and acquisitions of other companies, products or technologies at this time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista announces EC, Swissmedic approval for Ekterly
- Strong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals’ Ekterly
- Promising Launch of Ekterly Boosts KalVista Pharmaceuticals’ Market Potential
- KalVista price target raised to $28 from $27 at Citizens JMP
- KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch